Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 444

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

Open access
Lacouture, Mario E., Anadkat, Milan J., Bensadoun, René-Jean, Bryce, Jane, Chan, Alexandre, Epstein, Joel B., Eaby-Sandy, Beth, Murphy, Barbara A., MASCC Skin Toxicity Study Group·2011·Supportive Care in Cancer

Abstract

BACKGROUND: Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities. METHODS: A multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities. RESULTS: Prophylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible. CONCLUSION: Prevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients' health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00520-011-1197-6

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 70 references

Cited by

See all 444

Metadata

Authors
Lacouture, M. E., Anadkat, M. J., Bensadoun, R.-J., Bryce, J., Chan, A., Epstein, J. B., Eaby-Sandy, B., Murphy, B. A., & MASCC Skin Toxicity Study Group
Venue
Supportive Care in Cancer
Published
2011-06-01
Volume
19
Issue
8
Pages
1079-1095
ISSN
  • 0941-4355 (ISSN-L)
  • 1433-7339
OpenAlex
W2147513363
Cited by
444
References
70
FWCI
32.53
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. https://app.cochat.ai/papers/10.1007/s00520-011-1197-6
The paper
Lacouture, M. E., Anadkat, M. J., Bensadoun, R.-J., Bryce, J., Chan, A., Epstein, J. B., Eaby-Sandy, B., Murphy, B. A., & MASCC Skin Toxicity Study Group. (2011). Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Supportive Care in Cancer. https://doi.org/10.1007/s00520-011-1197-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.